

To: Veenstra, Gauke GE SC-CHSE-GV <Gauke.E.Veenstra@OPC.shell.com>  
From: Clegg, Patsy M SCC-CHSE-PC  
</O=SHELL/OU=MSXSCC/CN=RECIPIENTS/CN=PH197432>  
Cc: Tsai, Shan SP SHLOIL-SPS <sptsai@Shell.Com>; De Jong, Geert G SI-HE/2  
<Geert.G.deJong@SI.shell.com>; Cagen, Stuart Z SCC <szcagen@Shell.Com>; Boogaard, Peter J SI-HE/2  
<Peter.J.Boogaard@si.shell.com>; English, Timothy A SCC <taenglish@Shell.Com>  
Bcc:  
Received Date: 2002-02-18 16:14:23 GMT  
Subject: RE: feasibility study

---

Gauke,

The aromatics business position is for Shell to support this study being done. We should be actively involved in reviewing the report. This study would be added to the growing body of information that supports our need to further our involvement in product stewardship activities as evidenced by our support of the Shanghai Health Study.

I will leave technical comments to the technical experts addressed in your distribution list.

Thank you for keeping us updated.

Patsy Clegg  
Product Steward  
Shell Chemical LP  
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325  
Email: [pmclegg@shellus.com](mailto:pmclegg@shellus.com)  
Internet: <http://www.shell.com/chemicals>

-----Original Message-----

From: Veenstra, Gauke GE SC-CHSE-GV  
Sent: Monday, February 18, 2002 3:06 AM  
To: Tsai, Shan SP SHLOIL-SPS; De Jong, Geert G SI-HE/2; Cagen, Stuart Z  
SCC; Boogaard, Peter J SI-HE/2  
Cc: Clegg, Patsy M SCC-CHSE-PC  
Subject: FW: feasibility study

Dear all,

Just received this from Chris Money from Exxon Mobil.

I will participate in the CEFIC APA existing chem. group which meets on the 20th of February; I suspect that this will be discussed, although I expect not in great detail and no decision will be taken during this meeting. Let me have any comments you would want to introduce at this [early] stage. Chris Money asked me not to distribute this outside Shell.

Regards,  
Gauke Veenstra  
Toxicology Advisor  
Shell Chemicals Limited  
Shell Centre, London SE1 7NA, United Kingdom

Tel: +44 207 934 3448 Fax: 7627

Email: Gauke.E.Veenstra@OPC.Shell.com  
Internet: http://www.shell.com

-----Original Message-----

From: chris.money@exxonmobil.com [mailto:chris.money@exxonmobil.com]  
Sent: 18 February 2002 07:37  
To: jau@cefic.be; Bo.Dmytrasz@concauwe.be; Veenstra, Gauke GE SC-CHSE-GV;  
lpottenger@dow.com; cgi@cefic.be; Jacqueline.BAKES@atofina.com  
Cc: jan.urbanus@concauwe.be; roythorc@bp.com  
Subject: feasibility study

Dear All

I have just received from Rob Schnatter the final draft of the EMBSI report on the feasibility of conducting a pooled analysis on the HW, IOL and IP cohorts. You will recall that APA originally sponsored this work, resulting in a mtg of the P.I.'s from the UK IP, IOL and Health Watch cohorts at EMSI last July. In terms of process therefore, I suggest that the APA Existing Chemicals group takes the responsibility for initially looking at the document and providing any comments (including those which CONCAWE may have).

However, as the report is still at a draft stage, I think it would be sensible not to distribute this document widely. Once a final report is available, that will provide a better basis for wider discussions.

Christian, can we please add this to the agenda for the ECG mtg this Wednesday? Thanks

Chris Money  
Industrial Hygiene Advisor - Europe  
Exxon Mobil Petroleum & Chemical  
Hermeslaan 2  
B-1831 Machelen  
Belgium

Tel : +32(0)2 722 4230 (Fax : x3802)

Please note my Email has now changed to Chris.Money@ExxonMobil.com  
----- Forwarded by Chris Money/Benelux/ExxonMobil on 18/02/02 08:08 -----

A R Schnatter

To: Chris Money/Benelux/ExxonMobil@xom  
cc:  
18/02/02 06:29 Subject: feasibility study

Chris - here is a final draft of the feasibility study I promised you. I know you need it for APA. Why don't you circulate it there, and I'll do all the other formalities later. Monday is a co. holiday -- I'll be at home - 908-359-2385 if you need me. Rob(See attached file:

enhancedanal5Part1.doc)

Rob Schnatter  
908-730-1101  
Room LF-252  
Exxon Mobil Biomedical Sciences, Inc.  
1545 Route 22 East  
Annandale, NJ 08801-0971

---